<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37061998</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1591-9528</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Clinical and experimental medicine</Title><ISOAbbreviation>Clin Exp Med</ISOAbbreviation></Journal><ArticleTitle>Unique immune and inflammatory cytokine profiles may define long COVID syndrome.</ArticleTitle><Pagination><StartPage>2925</StartPage><EndPage>2930</EndPage><MedlinePgn>2925-2930</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10238-023-01065-6</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Long COVID is estimated to occur in 5-10% of individuals after acute SARS-CoV-2 infection. However, the pathophysiology driving the disease process is poorly understood.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We evaluated urine and plasma inflammatory and immune cytokine profiles in 33 individuals with long COVID compared to 33 who were asymptomatic and recovered, and 34 without prior infection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean urinary leukotriene E4 was significantly elevated among individuals with long COVID compared to asymptomatic and recovered individuals (mean difference 774.2&#xa0;pg/mL; SD 335.7) and individuals without prior SARS-CoV-2 infection (mean difference 503.1&#xa0;pg/ml; SD 467.7). Plasma chemokine ligand 6 levels were elevated among individuals with long COVID compared to individuals with no prior SARS-CoV-2 infection (mean difference 0.59 units; SD 0.42). We found no significant difference in angiotensin-converting enzyme 2 antibody levels. Plasma tumor necrosis factor receptor-associated factor 2 (TRAF2) levels were reduced among individuals with long COVID compared to individuals who were asymptomatic and recovered (mean difference&#x2009;=&#x2009;0.6 units, SD 0.46). Similarly, the mean level of Sarcoma Homology 2-B adapter protein 3 was 3.3 units (SD 1.24) among individuals with long COVID, lower&#xa0;than 4.2 units (SD 1.1) among individuals with recovered, asymptomatic COVID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings suggest that further studies should be conducted to evaluate the role of leukotriene E4 as a potential biomarker for a diagnostic test. Furthermore, based on reductions in TRAF2, long COVID may be driven in part by impaired TRAF2-dependent immune-mediated inflammation and potentially immune exhaustion.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allan-Blitz</LastName><ForeName>Lao-Tzu</ForeName><Initials>LT</Initials><AffiliationInfo><Affiliation>Division of Global Health Equity: Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. lallan-blitz@partners.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Omid</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kojima</LastName><ForeName>Noah</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saavedra</LastName><ForeName>Edwyn</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chellamuthu</LastName><ForeName>Prithivi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denny</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MacMullan</LastName><ForeName>Melanie A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hess</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shacreaw</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brobeck</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slepnev</LastName><ForeName>Vladimir I</ForeName><Initials>VI</Initials><AffiliationInfo><Affiliation>Curative Inc., San Dimas, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrayeva</LastName><ForeName>Albina</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klausner</LastName><ForeName>Jeffrey D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 AI169687</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL151493</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL159804</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Med</MedlineTA><NlmUniqueID>100973405</NlmUniqueID><ISSNLinking>1591-8890</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>75715-89-8</RegistryNumber><NameOfSubstance UI="D017999">Leukotriene E4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047992">TNF Receptor-Associated Factor 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.3.2.27</RegistryNumber><NameOfSubstance UI="D044767">Ubiquitin-Protein Ligases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017999" MajorTopicYN="N">Leukotriene E4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047992" MajorTopicYN="N">TNF Receptor-Associated Factor 2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044767" MajorTopicYN="N">Ubiquitin-Protein Ligases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibodies</Keyword><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Inflammatory cytokines</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Lao-Tzu Allan-Blitz and Noah Kojima have served as independent consultants for Curative Inc. Edwyn Saavedra, Prithvi Chellamuthu, Nicholas Denny, Melanie MacMullan, Maria Shacreaw, Matthew Brobeck, and Albina Ibrayeva are employees of Curative Inc. Jeffrey D. Klausner served as an independent medical director of Curative Inc. Frederick Turner and Vladimir Slepnev are shareholders of Curative Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>16</Day><Hour>14</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37061998</ArticleId><ArticleId IdType="pmc">PMC10105906</ArticleId><ArticleId IdType="doi">10.1007/s10238-023-01065-6</ArticleId><ArticleId IdType="pii">10.1007/s10238-023-01065-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022 Aug;28(8):1706&#x2013;1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus [Online]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1. Accessed 6 Oct 2021</Citation></Reference><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PLoS ONE. 2021;16(9):e0257016. doi: 10.1371/journal.pone.0257016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257016</ArticleId><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Doykov I, Hallqvist J, Gilmour KC, et al. 'The long tail of Covid-19'&#x2014;The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020;9:1349. doi: 10.12688/f1000research.27287.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.27287.1</ArticleId><ArticleId IdType="pmc">PMC7745182</ArticleId><ArticleId IdType="pubmed">33391730</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B, Tang N, Peluso MJ, et al. Characterization and biomarker analyses of post-COVID-19 complications and neurological manifestations. Cells. 2021 Feb 13; 10(2):386</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller C, Lin JC, Sheriff S, et al. Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy. Brain Imaging Behav. 2020;14(2):562&#x2013;572. doi: 10.1007/s11682-018-0029-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11682-018-0029-4</ArticleId><ArticleId IdType="pmc">PMC6612467</ArticleId><ArticleId IdType="pubmed">30617782</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol. 2022;23(2):210&#x2013;216. doi: 10.1038/s41590-021-01113-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01113-x</ArticleId><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams ES, Martins TB, Shah KS, et al. Cytokine deficiencies in patients with long-COVID. J Clin Cell Immunol. 2022;13(6): 672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9894377</ArticleId><ArticleId IdType="pubmed">36742994</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al. Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022:2022.08.09.22278592.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Austen KF, Maekawa A, Kanaoka Y, et al. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol. 2009;124(3):406&#x2013;414. doi: 10.1016/j.jaci.2009.05.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2009.05.046</ArticleId><ArticleId IdType="pmc">PMC2739263</ArticleId><ArticleId IdType="pubmed">19647860</ArticleId></ArticleIdList></Reference><Reference><Citation>Paruchuri S, Tashimo H, Feng C, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206(11):2543&#x2013;2555. doi: 10.1084/jem.20091240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20091240</ArticleId><ArticleId IdType="pmc">PMC2768854</ArticleId><ArticleId IdType="pubmed">19822647</ArticleId></ArticleIdList></Reference><Reference><Citation>Proost P, De Wolf-Peeters C, Conings R, et al. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J Immunol. 1993;150(3):1000&#x2013;1010. doi: 10.4049/jimmunol.150.3.1000.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.150.3.1000</ArticleId><ArticleId IdType="pubmed">8423327</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Dai Y, Zhang X, et al. CXCL6 regulates cell permeability, proliferation, and apoptosis after ischemia-reperfusion injury by modulating Sirt3 expression via AKT/FOXO3a activation. Cancer Biol Ther. 2021;22(1):30&#x2013;39. doi: 10.1080/15384047.2020.1842705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2020.1842705</ArticleId><ArticleId IdType="pmc">PMC7834049</ArticleId><ArticleId IdType="pubmed">33241954</ArticleId></ArticleIdList></Reference><Reference><Citation>Tejerina F, Catalan P, Rodriguez-Grande C, et al. Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19. BMC Infect Dis. 2022;22(1):211. doi: 10.1186/s12879-022-07153-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07153-4</ArticleId><ArticleId IdType="pmc">PMC8892394</ArticleId><ArticleId IdType="pubmed">35240997</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceulemans LJ, Khan M, Yoo SJ, et al. Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19. Lancet Respir Med. 2021;9(8):e78&#x2013;e79. doi: 10.1016/S2213-2600(21)00240-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00240-X</ArticleId><ArticleId IdType="pmc">PMC8189667</ArticleId><ArticleId IdType="pubmed">34118186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv [Preprint]. 2021 Jan 4:2020.11.03.367391</Citation></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, et al. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut. 2022;71(1):226&#x2013;229. doi: 10.1136/gutjnl-2021-324280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324280</ArticleId><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis. 2023;76(3):e487&#x2013;e490. doi: 10.1093/cid/ciac722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac722</ArticleId><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. Med. 2022;3(6):371&#x2013;387. doi: 10.1016/j.medj.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2022.04.001</ArticleId><ArticleId IdType="pmc">PMC9005383</ArticleId><ArticleId IdType="pubmed">35434682</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WJ, Su YW, Lu YC, et al. Crucial role for TNF receptor-associated factor 2 (TRAF2) in regulating NFkappaB2 signaling that contributes to autoimmunity. Proc Natl Acad Sci U S A. 2011;108(45):18354&#x2013;18359. doi: 10.1073/pnas.1109427108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1109427108</ArticleId><ArticleId IdType="pmc">PMC3215017</ArticleId><ArticleId IdType="pubmed">22042853</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou H, Li R, Hu H, et al. Modulation of regulatory T cell activity by TNF receptor Type II-targeting pharmacological agents. Front Immunol. 2018;9:594. doi: 10.3389/fimmu.2018.00594.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00594</ArticleId><ArticleId IdType="pmc">PMC5879105</ArticleId><ArticleId IdType="pubmed">29632537</ArticleId></ArticleIdList></Reference><Reference><Citation>Takaki S, Morita H, Tezuka Y, et al. Enhanced hematopoiesis by hematopoietic progenitor cells lacking intracellular adaptor protein. Lnk J Exp Med. 2002;195(2):151&#x2013;160. doi: 10.1084/jem.20011170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20011170</ArticleId><ArticleId IdType="pmc">PMC2193601</ArticleId><ArticleId IdType="pubmed">11805142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>